4,300 Women, Nine Countries, Three Skin Changes At Once: Galderma's Menopause Survey
Menopausal skin changes have long been treated as an afterthought in cosmetic dermatology. A new global survey from Galderma, presented at IMCAS 2026 in Paris between January 29 and 31, makes the case that they deserve a category of their own. The data is broad enough, and the emotional fallout serious enough, that the company has also pledged to fold menopausal status into all of its future injectable aesthetics clinical trials.
Who Was Surveyed
Galderma surveyed over 4,300 peri- and post-menopausal women aged 45 to 60 across nine countries: the United States, Brazil, Germany, the United Kingdom, Saudi Arabia, the United Arab Emirates, Egypt, China, and Thailand. Five continents, multiple skin types, and divergent cultural norms around aesthetic care. That breadth is what makes the patterns the survey identified worth attention.
Over Half Learned About Menopausal Skin By Experiencing It
The biggest knowledge gap the survey surfaced was educational. More than 50% of respondents said they learned about menopause’s effects on skin firsthand, not from a doctor or prior reading. Most discovered the impact in their 40s. Over 30% wished they had learned in their 30s. Over half rated themselves neutral or dissatisfied with their existing knowledge on the topic.
Three Skin Changes At Once, On Average
Women didn’t report a single dominant complaint. They averaged three skin changes simultaneously since menopause onset. Broken out by area:
- Lines and wrinkles: 59% face, 33% body
- Loss of firmness and elasticity: 58% face, 54% body
- Increased dryness: 56% face, 58% body
- Duller tone: 40% face, 30% body
Average severity was rated 6 out of 10. That number describes the in-between zone where the discomfort is real but not so severe that it pushes most women toward medical intervention. The reason multiple changes appear together is that estrogen decline simultaneously affects collagen production, sebum output, epidermal hydration, and microcirculation. They drop in concert.
The Emotional Toll Has Numbers Now
The survey quantified what dermatologists and gynecologists have heard anecdotally for decades. 60% of respondents felt less attractive. 57% reported more anxiety. 55% lost confidence. 46% said they wanted to socialize less. This is not vanity. It is the documented withdrawal from social and professional visibility that often accompanies the menopausal transition.
Notably, over 60% of respondents said they would have acted differently had they known earlier. That single statistic is the strongest case yet that menopausal skincare should begin in the mid-30s to early 40s, before the steepest drop in estrogen and collagen happens.
Treatment Preferences Lean Non-Invasive
Among treatments respondents would consider: 47% expressed interest in anti-wrinkle treatments, 41% in hyaluronic acid, 39% in skin quality treatments, and 30% in biostimulators. The notable pattern is what isn’t named at the top. Hormone replacement therapy and pharmaceutical interventions ranked behind topical, reversible aesthetic procedures. Many women appear to prefer treating skin complaints at the skin level, separate from the more comprehensive hormonal conversation.
A Pledge To Include Menopausal Status In Trials
The most significant downstream commitment Galderma announced is a structural one. The company will now include menopausal status as a variable in all of its injectable aesthetics clinical trials. Until now, the field has often ignored this variable, meaning the data on how the same treatment behaves before, during, and after menopause has been sparse. Fixing that gap is the long-tail outcome that may matter most for the next decade of women receiving these treatments.
What Mid-Life Skin Care Looks Like
The practical translation for women in their late 30s through 50s is unchanged but newly underlined. Daily SPF 50+, a vitamin C serum, and a tolerated retinoid (tretinoin 0.025-0.1% or retinol 0.5%) form a baseline. From the inside, plant-based estrogen sources like soy isoflavones and flaxseed lignans, plus vitamin D at 2,000 IU (50μg) or more and omega-3 with at least 1,000mg EPA, contribute to the metabolic environment in which skin renewal happens.
The shift the Galderma survey signals isn’t about a new ingredient. It’s about timing. The window in which prevention is meaningfully cheaper than correction closes around the start of perimenopause. The next phase of menopausal aesthetics will rely on the kind of stratified trial data Galderma just promised to produce.
Source
Galderma, “Galderma tackles menopause-related skin changes with global survey and clinical trial inclusivity” — https://www.galderma.com/news/galderma-tackles-menopause-related-skin-changes
Dermatology Times, “Galderma Prioritizes Menopause-Related Skin Health with New Data at IMCAS 2026”